Tools   Select Another Resource Report Type

http://www.simcyp.com/

Research based company providing predictive pharmacokinetic and pharmacodynamic tools, workshops and consultancy services. Their user-friendly simulator and databases predict drug absorption, clearance, distribution and metabolic drug-drug interactions from in vitro data. Simcyp's clients include major global pharmaceutical and bioscience companies, leading academic institutes and regulatory authorities. These clients form the Simcyp Consortium, which together with independent International Scientific Advisory Board, guide scientific development at Simcyp.Simcyp was acquired by Certara in 2012.

Proper citation: Simcyp (RRID:SCR_003944) Copy   

•   Source: SciCrunch Registry
  

http://www.biosolveit.de/

Commercial provider of software solutions for drug discovery applications offering tools, services, and research collaborations. The software portfolio ranges from design, over screening, to the visualization of ligand libraries, for hit identification, optimization, and scaffold hopping. With a stellar scientific advisory board and founders from academia who intensely collaborate with pharma, BioSolveIT catalyzes products off of university research successes with proven pharmaceutical industry application. They provide software products within the areas of ligand and structure-based drug design and is the pioneer of computational fragment-based ligand design. BioSolveIT innovate break-throughs in drug discovery by supplying smooth, user-centered designed tools bringing different researchers together for efficient multidisciplinary drug design.

Proper citation: BioSolveIT (RRID:SCR_003949) Copy   

•   Source: SciCrunch Registry
  

http://www.esteve.es/

A pharmaceutical chemical group in Spain with a presence worldwide. It operates in the pharmaceutical sector by researching and developing new drugs, marketing a wide range of ethical and OTC products, generics, vaccines and also products for hospital and veterinary use. Through its subsidiary Esteve Qu??mica is also present in the Active Pharmaceutical Ingredients sector.

Proper citation: ESTEVE (RRID:SCR_003948) Copy   

•   Source: SciCrunch Registry
  

http://www.lead-discovery.de/?lang=en

Commercial organization active in the field of pharmaceutical research that transforms promising early-stage projects into leads with initial proof-of-concept in animals. Focusing on small molecules, the LDC conducts drug discovery projects originating primarily from academic groups and sustains a preferred partnership with the Max Planck Society. Projects are developed in close collaboration with the project owner. LDC offers core expertise in Automation & Screening, Cellular Biology, Pharmacology and Medicinal Chemistry.

Proper citation: Lead Discovery Center (RRID:SCR_004113) Copy   

•   Source: SciCrunch Registry
  

http://www.chemaxon.com/

Commercial organization that provides cheminformatics software platforms, applications and services to optimize the value of chemistry information in life science and other R&D. This software enables structure visualization and management, property predictions and calculations, virtual synthesis, screening, clustering and drug design.

Proper citation: ChemAxon (RRID:SCR_004111) Copy   

•   Source: SciCrunch Registry
  

http://www.bioascent.com/

Commercial organization that specializes in compound management, compound logistic services, screening compound collection, and compound storage and retrieval. BioAscent enables drug discovery innovation; increasing lead finding opportunities through access to new chemical space; and providing compound management and logistics services that increase the value of existing collections.

Proper citation: BioAscent (RRID:SCR_004110) Copy   

•   Source: SciCrunch Registry
  

http://www.sygnaturediscovery.com/

Independent commercial provider of integrated drug discovery with core capabilities including medicinal chemistry, in vitro bioscience, computational chemistry and informatics. They also provide ADME (absorption, distribution, metabolism, and excretion), in vitro toxicology, early safety pharmacology, in vivo efficacy models, ion channel expertise, protein production and X-ray crystallography according to our clients'' specific needs, via long-term strategic alliance partners. They undertake complete drug discovery programs and hit finding, hit-to-lead and lead optimization projects.

Proper citation: Sygnature Discovery (RRID:SCR_004117) Copy   

•   Source: SciCrunch Registry
  

http://www.icdd-sas.com/

A contract research organization (CRO) that are mitochondrial experts, operating mitochondrial function screening platforms by using accepted pharmaceutical innovative technologies. The dynamic analysis of several typical markers of central and mitochondrial metabolism, redox status, or mitochondrial biogenesis are included in the determination of bioenergetic balance in living cells of human origin. These platforms are used to validate the activity of pharmaceuticals, cosmetics and environmental assets xenobiotics on mitochondrial targets associated with the activity or toxicity of these products under the selected models. They specialize in the selection of drugs affecting the progression of neurodegenerative diseases and offer proven models of Huntington's disease, Parkinson's and Alzheimer's, using primary cells of human origin. They have developed and use technology cellulomique and proteomics to identify early response profiles and clinical safety of pharmaceutical products for diseases of the CNS.

Proper citation: Innovative Concepts in Drug Development (RRID:SCR_003940) Copy   

•   Source: SciCrunch Registry
  

http://www.mercachem.com/

Privately owned European contract research organization offering innovative chemistry, medicinal chemistry and early process research services to accelerate drug discovery and development. They provide a wide range of chemical services specializing in exclusive synthetic and process chemistry services to support research and development programs of companies across the globe. Name changed to Symeres after merger of Mercachem and Syncom., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Mercachem (RRID:SCR_004114) Copy   

•   Source: SciCrunch Registry
  

http://www.mosaicsystems.nl/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on October 21, 2014. Commercial organization that provides technology, tools, and services for the development and production of biologics from therapeutics and drugs, food ingredients, and agriculture products. The company specializes in biologics separation and purification. Its products are used for industrial process chromatography applications. (Businessweek)

Proper citation: Mosaic Systems (RRID:SCR_003934) Copy   

•   Source: SciCrunch Registry
  

http://biorxiv.org/

A free archive and distribution service for unpublished preprints in the life sciences allowing authors to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals. An article may be posted prior to, or concurrently with, submission to a journal but should not be posted if it has already been published. Once an article is published in a journal, bioRxiv will update the preprint with a link to the published version.

Proper citation: bioRxiv (RRID:SCR_003933) Copy   

•   Source: SciCrunch Registry
  

http://git-scm.com/

A free and open source distributed version control system designed to handle everything from small to very large projects with speed and efficiency. Git is easy to learn and has a tiny footprint with lightning fast performance. It outclasses SCM tools like Subversion, CVS, Perforce, and ClearCase with features like cheap local branching, convenient staging areas, and multiple workflows.

Proper citation: Git (RRID:SCR_003932) Copy   

•   Source: SciCrunch Registry
  

http://www.alzheimer-hellas.gr/english.php

A non-profit organization whose aim is to offer advice concerning the care of Alzheimer''''s disease patients, information and services for the people affected and their families. Also, to offer mutual help to the family members of the patients in order to reduce the social, economic and emotional cost deriving from the long care of people suffering from dementia. Lastly, the association attempts to publicize the social needs of the population affected and to inform the public in order to be acquainted with the problem. The mission of the Greek Association of Alzheimer''''s Disease is * the early diagnosis of dementia by scientists * the promotion of research * education and training for all the stakeholders * the development of Care Units for patients with Alzheimer''''s Disease * the provision of useful information and advise (24 hour help-line) on dementia problems (caring, legal or financial issues) * the presentation of lectures by health professionals and informal carers, covering all aspects of Alzheimer Disease * and the development of professional seminars during the whole year.

Proper citation: Greek Association of Alzheimers Disease and Related Disorders (RRID:SCR_003938) Copy   

•   Source: SciCrunch Registry
  

http://www.eisai.com/

A global pharmaceutical company.

Proper citation: Eisai (RRID:SCR_003936) Copy   

•   Source: SciCrunch Registry
  

http://www.sartorius.com/

Commercial organization that provides laboratory and process technologies and equipment. Their products and services help customers around the globe implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries.

Proper citation: Sartorius (RRID:SCR_003935) Copy   

•   Source: SciCrunch Registry
  

http://www.iars.org/home/

The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia-related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly Anesthesia & Analgesia journal in print and online. The IARS mission is to encourage, stimulate, and fund ongoing anesthesia-related research projects that will enhance and advance the specialty, and to disseminate current, state-of-the art, basic and clinical research data in all areas of clinical anesthesia, including perioperative medicine, critical care, and pain management. The IARS is focused solely on the advancement and support of education and scientific research related to anesthesiology. To fulfill this mission the Society publishes a monthly scientific journal, Anesthesia & Analgesia, conducts an annual clinical and scientific meeting, funds anesthesia-related research, and sponsors the SmartTots research initiative.

Proper citation: International Anesthesia Research Society (RRID:SCR_004146) Copy   

•   Source: SciCrunch Registry
  

http://www.beactica.com/

A drug discovery company utilizing its methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. They offer expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using their proprietary Sprint platform.

Proper citation: Beactica (RRID:SCR_004024) Copy   

•   Source: SciCrunch Registry
  

http://www.bdi.ie/

An academic-business-clinical partnership that sponsors research programs focused on the development of next-generation biomedical diagnostic devices. They aim to transform healthcare by pioneering advances in the science and technology of diagnostics and by translating these advances into clinical use. Building on key scientific insights, the BDI will now apply its established capabilities to create integrated Point-of-Care solutions, which will have major impacts on diagnosing disease and sustaining human health.

Proper citation: Biomedical Diagnostics Institute (RRID:SCR_004022) Copy   

•   Source: SciCrunch Registry
  

http://www.baxter.com/

A global healthcare company with expertise in medical devices, pharmaceuticals and biotechnology. Through its subsidiaries, they develop, manufacture and market products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. BioScience Baxter is a manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. Baxter''s Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter''s Medical Products business is a leader in Renal home-based therapies, such as peritoneal dialysis, and offers other products and services for people with end-stage kidney disease.

Proper citation: Baxter (RRID:SCR_003974) Copy   

•   Source: SciCrunch Registry
  

http://www.wikigenes.org/e/art/e/258.html

Consortium to discover and map the genes that contribute to Alzheimer's disease and completely understand the role inheritance plays. To achieve this goal, they will work to identify all the genes that contribute to the risk of developing this disease. Investigators will have access to combined genetic data from a large number of Alzheimer's disease subjects and compare it to genetic data from an equally large number of elderly people who do not have Alzheimer's. In the initial phase of the work, more than 20,000 people with Alzheimer's and about 20,000 healthy elderly subjects will be compared. As the study progresses, 10,000 additional people with Alzheimer's and the same number of healthy elderly subjects will be added to the study. The subjects for these studies come from different Alzheimer research project locations across Europe, the UK, the US, and Canada. Data is available from their 2014 publication in Translational Psychiatry at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944635/ (http://www.ncbi.nlm.nih.gov/pubmed/24495969) Currently, there is no public access to the raw individual level genetic data because of privacy considerations. Researchers working with US cohorts deposit data in the database of genotypes and phenotypes (dbGaP), where it is available to all researchers who can show that they are able to guarantee the security of the data. After scanning the DNA of over 74,000 patients and controls from 15 countries, the IGAP consortium reported 11 new regions of the genome involved in late-onset Alzheimer's disease. IGAP published its results in Nature Genetics on October 27, http://www.ncbi.nlm.nih.gov/pubmed/24162737

Proper citation: International Genomics of Alzheimers Project (RRID:SCR_004029) Copy   

•   Source: SciCrunch Registry